8-K: Apyx Medical Reports Q2 2024 Results with Revenue Decline and Updated Full-Year Outlook

Apyx Medical reported a 10% year-over-year decrease in total revenue for the second quarter of 2024, alongside an updated full-year financial outlook.

Summary

• Apyx Medical's total revenue for Q2 2024 was $12.1 million, a 10% decrease compared to the same period last year.
• Advanced Energy revenue decreased by 17% year-over-year to $9.8 million, while OEM revenue increased by 29% to $2.4 million.
• The company experienced a net loss attributable to stockholders of $6.6 million, a significant increase from the $1.0 million loss in Q2 2023, which included a $2.7 million gain from a sale-leaseback.
• Adjusted EBITDA loss was $4.3 million, compared to a $1.6 million loss in the same quarter of the previous year.
• For the first six months of 2024, total revenue decreased by 13% to $22.4 million.
• The company has updated its full-year 2024 revenue guidance to a range of $50.6 million to $52.1 million, representing a decrease of approximately 3% to 0% year-over-year.
• The updated full-year net loss attributable to stockholders is projected to be between $23.5 million and $24.5 million.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with significant revenue declines and increased losses, but also highlights growth in handpiece sales and strategic initiatives. The overall sentiment is cautiously negative due to the financial challenges.

Positives

• OEM revenue increased by 29% in Q2 2024, demonstrating growth in that segment.
• Global sales of Advanced Energy handpieces increased by more than 20% year-over-year.
• The company expects low double-digit growth in global handpiece sales for the full year.
• Apyx Medical launched the Renewing Lives campaign, a give-back program providing Renuvion treatments.
• The company is focused on managing operating expenses and cash burn.
• The company is preparing to introduce a new platform in the near future.

Negatives

• Total revenue decreased by 10% in Q2 2024 compared to the same period last year.
• Advanced Energy revenue decreased by 17% year-over-year.
• Net loss attributable to stockholders increased significantly to $6.6 million in Q2 2024.
• Adjusted EBITDA loss increased to $4.3 million in Q2 2024.
• Gross profit margin decreased to 61.7% from 68.4% in the prior year period.
• The company is experiencing a challenging environment in the cosmetic surgery market.
• Global sales of Advanced Energy generators were impacted by delays in capital equipment investments by surgeons.

Risks

• The company is facing a challenging environment in the cosmetic surgery market, impacting Advanced Energy sales.
• Economic uncertainty is causing prospective surgeon customers to delay investments in new capital equipment.
• The company's financial performance is subject to risks related to regulatory approvals, supply chain disruptions, and macroeconomic conditions.
• Increased interest expense on higher outstanding borrowings is negatively impacting the company's financials.
• The company's net loss has increased significantly compared to the previous year.

Future Outlook

The company expects global Advanced Energy generator sales to remain impacted by the challenging market environment, but anticipates low double-digit growth in global handpiece sales for the full year. The company has updated its full-year revenue guidance to a range of $50.6 million to $52.1 million and expects a net loss attributable to stockholders between $23.5 million and $24.5 million.

Management Comments

• Charlie Goodwin, President and Chief Executive Officer, stated that Advanced Energy sales performance reflects the challenging environment in the cosmetic surgery market.
• Mr. Goodwin noted that global sales of Advanced Energy generators were impacted by delays in capital equipment investments.
• Mr. Goodwin highlighted the strong growth in global sales of Advanced Energy handpieces, which increased more than 20% year-over-year.
• Stavros Vizirgianakis, Chairperson of the Board of Directors, mentioned initiatives to improve stockholder value and create a longer runway for the company.
• Mr. Vizirgianakis stated that the company is focused on promoting its Renuvion technology and managing operating expenses.

Industry Context

The report indicates a challenging environment in the cosmetic surgery market, which is impacting Apyx Medical's Advanced Energy sales. This suggests a broader trend of economic uncertainty affecting capital equipment investments in the aesthetics industry. The company's focus on handpiece sales and direct-to-consumer marketing reflects a strategic shift to mitigate the impact of reduced generator sales.

Comparison to Industry Standards

• The decrease in Apyx Medical's Advanced Energy revenue is likely reflective of a broader trend in the medical aesthetics industry, where capital equipment sales are often sensitive to economic conditions.
• Companies like Cynosure and Cutera, which also offer energy-based aesthetic devices, may be experiencing similar challenges in generator sales.
• However, the 20% growth in handpiece sales for Apyx Medical is a positive sign, indicating continued demand for consumables associated with their technology.
• The company's focus on direct-to-consumer marketing and B2B initiatives is a common strategy in the medical aesthetics space to drive utilization and awareness.
• The updated full-year revenue guidance suggests that Apyx Medical is adjusting to the current market conditions, which is a common practice among publicly traded companies in the sector.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the decreased revenue and increased net loss.
• Employees may be affected by the company's focus on managing operating expenses.
• Customers may benefit from the company's new marketing initiatives and the Renewing Lives campaign.
• Suppliers may be impacted by changes in the company's sales and production volumes.

Next Steps

• The company will continue to focus on promoting its Renuvion technology through marketing initiatives.
• Apyx Medical will manage operating expenses and cash burn.
• The company plans to introduce a new platform in the near future.
• Management will host a conference call to discuss the results and answer questions.

Key Dates

Keywords

Renuvion, Apyx Medical, Advanced Energy, OEM, Financial Results, EBITDA, Net Loss, Revenue, Medical Devices, Cosmetic Surgery